Contrasting Pacira Biosciences (NASDAQ:PCRX) & Vanda Pharmaceuticals (NASDAQ:VNDA)

Pacira Biosciences (NASDAQ:PCRX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Earnings & Valuation

This table compares Pacira Biosciences and Vanda Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacira Biosciences $337.28 million 5.63 -$470,000.00 $0.29 157.03
Vanda Pharmaceuticals $193.12 million 4.60 $25.20 million $0.48 34.73

Vanda Pharmaceuticals has lower revenue, but higher earnings than Pacira Biosciences. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Pacira Biosciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Insider & Institutional Ownership

99.1% of Pacira Biosciences shares are owned by institutional investors. Comparatively, 99.3% of Vanda Pharmaceuticals shares are owned by institutional investors. 5.8% of Pacira Biosciences shares are owned by company insiders. Comparatively, 8.2% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares Pacira Biosciences and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacira Biosciences 0.55% 10.19% 4.54%
Vanda Pharmaceuticals 55.49% 38.90% 31.81%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pacira Biosciences and Vanda Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira Biosciences 1 4 6 0 2.45
Vanda Pharmaceuticals 1 3 0 0 1.75

Pacira Biosciences presently has a consensus target price of $53.10, suggesting a potential upside of 16.60%. Vanda Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 19.98%. Given Vanda Pharmaceuticals’ higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Pacira Biosciences.


Vanda Pharmaceuticals beats Pacira Biosciences on 8 of the 14 factors compared between the two stocks.

About Pacira Biosciences

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit